Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure

J Cardiovasc Pharmacol. 2003 Feb;41(2):151-7. doi: 10.1097/00005344-200302000-00001.


Extended-release (ER) metoprolol succinate is a controlled-release formulation designed to deliver metoprolol succinate at a near constant rate for approximately 20 h, independent of food intake and gastrointestinal pH. Once-daily dosing of ER metoprolol succinate 12.5-200 mg produces even plasma concentrations over a 24-h period, without the marked peaks and troughs characteristically observed with the immediate-release (IR) formulation. This leads to consistent beta1-blockade over 24 h, while maintaining cardioselectivity at doses up to 200 mg daily. Pharmacokinetic studies have also been performed in heart failure patients and have demonstrated that ER metoprolol succinate is associated with a more pronounced and even beta1-blockade over a 24-h period than the IR formulation. The efficacy and good tolerability of ER metoprolol succinate in heart failure patients has now been demonstrated in a large-scale clinical trial.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemistry, Pharmaceutical
  • Delayed-Action Preparations / pharmacokinetics
  • Delayed-Action Preparations / therapeutic use
  • Heart Failure / blood
  • Heart Failure / drug therapy
  • Heart Failure / metabolism*
  • Humans
  • Metoprolol / analogs & derivatives*
  • Metoprolol / blood
  • Metoprolol / pharmacokinetics*
  • Metoprolol / therapeutic use


  • Delayed-Action Preparations
  • Metoprolol